Federal Law No. 2 of 2019 keeps health data on servers inside the country, and DHA, DOH, and MOHAP each require integration with their information exchange. Digital health teams here need evidence clinicians trust, a way to keep learning after launch, and infrastructure that respects the border. Weaxen is built for all three.
Under Federal Law No. 2 of 2019, health information tied to UAE services must be stored on UAE soil — and integrated with NABIDH in Dubai, Malaffi in Abu Dhabi, or Riyati for MOHAP. A product built on offshore cloud is in breach from its first consultation. Residency isn't a procurement nicety; it's a gating requirement.
A roadmap argument that works in consumer SaaS dies in a clinical review. Clinicians and medical directors expect real evidence — literature, users, clinical reality — weighed and cited. Getting to that depth is the work most teams underestimate.
Launch is the start of the evidence, not the end. Real-world use surfaces signals that should shape the next version. Yet most teams freeze their evidence at go-live and have no mechanism to learn from what happens next.
UAE healthcare buyers can't take residency claims on trust — the law won't let them. This is Weaxen's posture, stated plainly:
Held in-region and, where UAE law or your policy requires it, on UAE soil — encrypted in transit and at rest. Data residency is part of how we deploy, not a special case.
Encrypted in transit and at rest, MFA everywhere, and on enterprise agreements SAML 2.0 single sign-on with DNS-verified domains and optional enforcement.
Organisation-level audit logging of access and configuration changes, plus versioned artefacts for every product decision.
Weaxen holds your product research and decisions, not patient records — reducing your exposure while keeping the workspace itself in-region.
Working to DHA, DOH, or MOHAP requirements? Bring the residency and integration constraints early and we'll scope the deployment around them: security@mindlace.co.uk.
Teams describe what they're building in plain language. No taxonomy to learn, no template to fill.
Path Forger recommends the right artefacts for your stage and risk level. A scrappy pre-seed run looks different to a Series A launch — same engine, right dose.
Every decision documented. Every assumption surfaced. Every risk traceable. Ready for engineers, boards, or Claude Code.
Yes. Where UAE law or your policy requires it, your workspace data is held on-soil in the UAE, encrypted in transit and at rest. Data residency is part of how we deploy, not a special case.
No. Weaxen holds your product research, strategy, and decision records — not patient records or clinical data — which keeps you clear of the heaviest data obligations while still respecting in-country residency for the workspace itself.
RACI and phase sign-off are built into the framework, and every artefact is versioned with its evidence attached — which maps naturally onto clinical safety and quality-management reviews.
Self-serve to explore, same day. For an on-soil deployment, bring your residency and HIE-integration constraints early and we'll scope it with you.
For teams who treat "build the right thing" as a precondition, not a slogan. Start for free →